secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001193125-23-064582
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma gets Nasdaq extension to Sept 5, 2023 for bid price compliance
--------------------------------------------------------------------------------

- Nasdaq granted Benitec an additional 180-day period until Sept 5, 2023 to meet the $1.00 minimum bid price rule.
- Company failed to cure the bid price deficiency by the original deadline of March 6, 2023.
- Compliance requires closing bid price of at least $1.00 for 10 consecutive business days during extension.
- If not compliant by Sept 5, 2023, Nasdaq will begin delisting; Benitec may appeal to a hearings panel.
- Benitec may consider a reverse stock split as a potential cure for the bid price deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523064582/0001193125-23-064582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523064582/d484132d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-064582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer